CalciMedica Inc. (NASDAQ:CALC) Receives Average Rating of “Hold” from Analysts

Shares of CalciMedica Inc. (NASDAQ:CALC) have been assigned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $50.00.

Several research firms have issued reports on CALC. Weiss Ratings raised CalciMedica from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 27th. Wall Street Zen lowered CalciMedica from a “sell” rating to a “strong sell” rating in a research note on Saturday, September 12th. UBS Group reiterated a “neutral” rating on shares of CalciMedica in a report on Thursday, August 13th. Guggenheim initiated coverage on CalciMedica in a research report on Thursday, August 20th. They set a “buy” rating for the company. Finally, HC Wainwright restated a “neutral” rating on shares of CalciMedica in a report on Wednesday, July 29th.

CalciMedica Stock Performance

CalciMedica stock opened at $1.30 on Friday. The firm has a 50 day simple moving average of $2.45 and a 200-day simple moving average of $3.22. CalciMedica has a 1-year low of $1.30 and a 1-year high of $36.00. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.58 and a quick ratio of 5.58. The stock has a market cap of $8.88 million, a price-to-earnings ratio of -0.19 and a beta of 0.76.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.97. On average, analysts expect that CalciMedica will post -5.25 EPS for the current year.

Institutional Investors Weigh In On CalciMedica

An institutional investor recently raised its stake in CalciMedica stock. Renaissance Technologies LLC boosted its stake in CalciMedica Inc. (NASDAQ:CALC) by 45.0% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 128,075 shares of the company’s stock after purchasing an additional 39,775 shares during the period. Renaissance Technologies LLC owned about 0.81% of CalciMedica worth $69,000 at the end of the most recent quarter.

CalciMedica Company Profile

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious inflammatory and immune-mediated diseases. The company’s research centers on calcium release-activated calcium (CRAC) channels, which play a role in the activation of immune cells and the inflammatory response.

CalciMedica’s lead product candidate is zelnecirnon, formerly known as Auxora or CM4620. It is an investigational, selective CRAC channel inhibitor being studied for acute and chronic inflammatory conditions, including severe acute pancreatitis and acute kidney injury associated with severe inflammatory illness.